As tumors grow, they acquire mutations, some of which create neoantigens that influence
the response of patients to immune checkpoint inhibitors. We explored the impact of …

Background Among patients with non–small-cell lung cancer (NSCLC), data on intratumor
heterogeneity and cancer genome evolution have been limited to small retrospective cohorts. …

Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-programmed
cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or anti-…

Treatment with monoclonal antibody specific for cytotoxic T lymphocyte–associated antigen
4 (CTLA-4), an inhibitory receptor expressed by T lymphocytes, has emerged as an effective …

The early detection of relapse following primary surgery for non-small-cell lung cancer and
the characterization of emerging subclones, which seed metastatic sites, might offer new …

CD4+ CD25+ regulatory T cells (T reg) are potent immunosuppressive cells that are pivotal
in the regulation of peripheral tolerance. In this report, we identify granzyme B (GZ-B) as one …

Cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) is a critical negative regulator of
immune responses. Uniquely among known inhibitory receptors, its genetic ablation results in a …

Adoptive transfer of large numbers of tumor-reactive CD8 + cytotoxic T lymphocytes (CTLs)
expanded and differentiated in vitro has shown promising clinical activity against cancer. …

Checkpoint inhibitors (CPIs) augment adaptive immunity. Systematic pan-tumor analyses
may reveal the relative importance of tumor-cell-intrinsic and microenvironmental features …

The mechanisms by which melanoma and other cancer cells evade anti-tumor immunity
remain incompletely understood. Here, we show that the growth of tumors formed by mutant …